The global pandemic caused by the SARS-CoV-2 has resulted in an increased incidence of venous thromboembolism among hospitalized COVID-19-patients, especially those who required intensive care, despite thromboprophylaxis. This has resulted in the use of higher doses of thromboprophylaxis or therapeutic anticoagulation therapy even in the absence of thrombotic events. However, after their hospital discharge, authors and current guidelines are not unanimous about extended anticoagulant therapy in patients with COVID-19. Here, we report two pulmonary embolism cases following hospitalization for COVID-19, despite intermediate doses of thromboprophylaxis. These rare cases suggest that there may be a residual thrombotic risk following hospitalization for COVID-19 and highlight questions about extended prophylactic-anticoagulation therapy after hospital discharge of patients with COVID-19.
【저자키워드】 COVID-19, Case report, Coagulopathy, Pulmonary embolism, Post-discharge, 【초록키워드】 therapy, Hospitalized, intensive care, Hospitalization, Venous Thromboembolism, global pandemic, incidence, Thrombotic events, therapeutic anticoagulation, Thromboprophylaxis, dose, anticoagulant therapy, hospital discharge, intermediate dose, thrombotic risk, highlight, caused, required, question, absence, patients with COVID-19, the SARS-CoV-2, 【제목키워드】 Hospitalization,